ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer
Adding relacorilant, a drug that blocks the cortisol receptor and thereby restores chemotherapy sensitivity, to nab-paclitaxel lengthened progression-free and overall survival in platinum-resistant ovarian cancer regardless of any biomarker.
Overview
Phase 3 trial of 381 patients with platinum-resistant ovarian cancer and one to three prior lines randomised to intermittent relacorilant plus nab-paclitaxel or nab-paclitaxel alone.
Median progression-free survival was 6.54 versus 5.52 months (hazard ratio 0.70) and interim median overall survival 15.97 versus 11.50 months (hazard ratio 0.69), with a similar safety profile between arms.
- Median progression-free survival 6.54 vs 5.52 months; hazard ratio 0.70.
- Interim median overall survival 15.97 vs 11.50 months; hazard ratio 0.69.
Relacorilant with nab-paclitaxel is a new option for platinum-resistant disease that does not depend on folate receptor status, with regulatory review following the trial.
- Open-label design.
- Overall survival analysis was interim.
Similar pages
not linked directly; found by shared links- CompanyCorcept Therapeutics
Shares ROSELLA / GOG-3073, Relacorilant.